|drug966||DAS181 COVID-19 Wiki||1.00|
|drug967||DAS181 OL Wiki||1.00|
|drug3170||Standard Care Therapy Wiki||1.00|
|D012141||Respiratory Tract Infections NIH||0.17|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
Description: Removal of all oxygen support (with stable SpO2)Measure: Percent of subjects who Return to Room Air (RTRA) (main study) Time: by Day 28
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports